GlassScriptPhysician profile
John L Laubenthal
NPI 1528064458
$3,843.19
in general payments reported to CMS, 2019-2025
11 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $409 · 2021: $560 · 2022: $801 · 2023: $436 · 2024: $645 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.30 | 2021-2025 | |
| Allergan, INC. | $838.16 | 2019-2020 | |
| Axsome Therapeutics, INC. | $453.20 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $433.81 | 2021-2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $216.87 | 2022-2024 | Quviviq |
| Tris Pharma INC | $216.11 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Takeda Pharmaceuticals U.S.A., INC. | $136.07 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $101.40 | 2022 | |
| Eisai INC. | $67.82 | 2020-2021 | |
| Stimwave Technologies Incorporated | $58.19 | 2019 | |
| Shire North American Group INC | $18.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Laubenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.